Key Health Care Antitrust and Competition Takeaways from ASHEcon 2025
Focusing on the intersection of academic research and litigation matters, Daniel Shack and Annabelle Fowler highlight key research developments and discussion...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s policy team provides analysis and insights into global, regional and national policy issues affecting patients, the healthcare system, and the life sciences industry. CRA has a reputation for independence and rigor, benefiting from long standing relationships with most leading life sciences organizations as well as national governments and the European Commission and industry associations. Our specialist team has provided unique policy oversight for the past 20 years delivering high quality, robust analysis in a compelling fashion that is accessible to the target audience, whomever it may be.
Focusing on the intersection of academic research and litigation matters, Daniel Shack and Annabelle Fowler highlight key research developments and discussion...
US policy has long recognized this challenge, beginning with the Orphan Drug Act of 1983 and continuing with recent exemptions for certain orphan indications...
Ryan Lawlor presents the session titled “Prioritising Alzheimer’s Disease in Europe: Next steps for Policy Action.” Tim Wilsdon moderates the panel discussion...
Annabelle Fowler presents the CRA paper titled “An Analysis of Medicaid CPI Rebates and the Sustainability of U.S. Generic Markets.” Ashutosh Mishra presents...